Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR-ICE (zanubrutinib + rituximab/ifosfamide/carboplatin/etoposide) in relapsed/refractory diffuse large B cell lymphoma
KCT0008562Phase 2Not yet recruiting
- Sponsor
- BeiGene
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by BeiGene. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0008562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008562.